161 related articles for article (PubMed ID: 25426663)
1. Risk factors for tumor lysis syndrome in childhood acute myeloid leukemia treated with a uniform protocol without rasburicase prophylaxis.
Kishimoto K; Kobayashi R; Ichikawa M; Sano H; Suzuki D; Yasuda K; Iguchi A; Kobayashi K
Leuk Lymphoma; 2015 Jul; 56(7):2193-5. PubMed ID: 25426663
[No Abstract] [Full Text] [Related]
2. Management of tumour lysis syndrome in children: what is the evidence for prophylactic rasburicase in non-hyperleucocytic leukaemia?
Agrawal AK; Feusner JH
Br J Haematol; 2011 Apr; 153(2):275-7. PubMed ID: 21255003
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
4. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
5. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rasburicase in hematologic malignancies.
Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
[TBL] [Abstract][Full Text] [Related]
7. Rasburicase for the management of tumor lysis syndrome in neonates.
McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
[TBL] [Abstract][Full Text] [Related]
8. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
9. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
[TBL] [Abstract][Full Text] [Related]
10. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
[TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome, case report and review of the literature.
Masera G; Jankovic M
Ann Oncol; 1997 Jan; 8(1):97. PubMed ID: 9093714
[No Abstract] [Full Text] [Related]
17. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
[No Abstract] [Full Text] [Related]
18. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings-Efficacy of a fixed low-dose rasburicase.
Gopakumar KG; Thankamony P; Seetharam S; P K
Pediatr Hematol Oncol; 2017 May; 34(4):206-211. PubMed ID: 28872997
[TBL] [Abstract][Full Text] [Related]
19. A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.
Majumdar S; Sharma N; Sengar M; Thorat J; Nayak L; Bonda A; Bagal B; Rajendra A; Sethi A; Jain H
Leuk Lymphoma; 2023 Mar; 64(3):628-638. PubMed ID: 36891578
[TBL] [Abstract][Full Text] [Related]
20. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.
Wang LY; Shih LY; Chang H; Jou ST; Lin KH; Yeh TC; Lin SF; Liang DC
Acta Haematol; 2006; 115(1-2):35-8. PubMed ID: 16424647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]